Annual CFO
-$30.33 M
+$26.31 M+46.46%
December 31, 2023
Summary
- As of February 7, 2025, ALDX annual cash flow from operations is -$30.33 million, with the most recent change of +$26.31 million (+46.46%) on December 31, 2023.
- During the last 3 years, ALDX annual CFO has risen by +$7.17 million (+19.12%).
- ALDX annual CFO is now -3797.96% below its all-time high of -$778.00 thousand, reached on December 31, 2012.
Performance
ALDX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$7.97 M
+$5.25 M+39.70%
September 30, 2024
Summary
- As of February 7, 2025, ALDX quarterly cash flow from operations is -$7.97 million, with the most recent change of +$5.25 million (+39.70%) on September 30, 2024.
- Over the past year, ALDX quarterly CFO has increased by +$50.00 thousand (+0.62%).
- ALDX quarterly CFO is now -1693.71% below its all-time high of $500.40 thousand, reached on December 31, 2023.
Performance
ALDX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$30.67 M
+$50.00 K+0.16%
September 30, 2024
Summary
- As of February 7, 2025, ALDX TTM cash flow from operations is -$30.67 million, with the most recent change of +$50.00 thousand (+0.16%) on September 30, 2024.
- Over the past year, ALDX TTM CFO has increased by +$11.39 million (+27.07%).
- ALDX TTM CFO is now -10192.45% below its all-time high of -$298.00 thousand, reached on March 31, 2013.
Performance
ALDX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
ALDX Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +46.5% | +0.6% | +27.1% |
| 3 y3 years | +19.1% | +5.4% | +21.9% |
| 5 y5 years | -1.6% | +4.1% | +31.8% |
ALDX Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +46.5% | -1693.7% | +60.0% | -1.1% | +46.2% |
| 5 y | 5-year | at high | +46.5% | -1693.7% | +60.0% | -1.1% | +46.2% |
| alltime | all time | -3798.0% | +46.5% | -1693.7% | +60.0% | <-9999.0% | +46.2% |
Aldeyra Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.97 M(-39.7%) | -$30.67 M(-0.2%) |
| Jun 2024 | - | -$13.22 M(+32.6%) | -$30.72 M(-0.4%) |
| Mar 2024 | - | -$9.97 M(-2092.9%) | -$30.86 M(+1.7%) |
| Dec 2023 | -$30.33 M(-46.5%) | $500.40 K(-106.2%) | -$30.33 M(-27.9%) |
| Sep 2023 | - | -$8.02 M(-39.9%) | -$42.06 M(-9.8%) |
| Jun 2023 | - | -$13.36 M(+41.4%) | -$46.61 M(-12.4%) |
| Mar 2023 | - | -$9.44 M(-15.9%) | -$53.21 M(-6.1%) |
| Dec 2022 | -$56.64 M(+33.1%) | -$11.23 M(-10.7%) | -$56.64 M(-0.6%) |
| Sep 2022 | - | -$12.57 M(-37.0%) | -$56.98 M(+7.8%) |
| Jun 2022 | - | -$19.96 M(+55.0%) | -$52.84 M(+25.9%) |
| Mar 2022 | - | -$12.87 M(+11.2%) | -$41.96 M(-1.4%) |
| Dec 2021 | -$42.56 M(+13.5%) | -$11.58 M(+37.3%) | -$42.56 M(+8.3%) |
| Sep 2021 | - | -$8.43 M(-7.0%) | -$39.30 M(+5.9%) |
| Jun 2021 | - | -$9.07 M(-32.7%) | -$37.10 M(+4.2%) |
| Mar 2021 | - | -$13.47 M(+62.0%) | -$35.61 M(-5.0%) |
| Dec 2020 | -$37.49 M(-16.7%) | -$8.32 M(+33.3%) | -$37.49 M(-7.2%) |
| Sep 2020 | - | -$6.24 M(-17.7%) | -$40.40 M(-4.9%) |
| Jun 2020 | - | -$7.58 M(-50.7%) | -$42.48 M(-11.0%) |
| Mar 2020 | - | -$15.36 M(+36.8%) | -$47.71 M(+6.1%) |
| Dec 2019 | -$44.98 M(+50.7%) | -$11.23 M(+35.0%) | -$44.98 M(+7.8%) |
| Sep 2019 | - | -$8.31 M(-35.1%) | -$41.73 M(+1.5%) |
| Jun 2019 | - | -$12.81 M(+1.4%) | -$41.10 M(+19.0%) |
| Mar 2019 | - | -$12.63 M(+58.5%) | -$34.53 M(+15.7%) |
| Dec 2018 | -$29.86 M | -$7.97 M(+3.6%) | -$29.86 M(+11.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$7.69 M(+23.1%) | -$26.91 M(+12.5%) |
| Jun 2018 | - | -$6.25 M(-21.5%) | -$23.92 M(+4.1%) |
| Mar 2018 | - | -$7.95 M(+58.5%) | -$22.99 M(+19.6%) |
| Dec 2017 | -$19.22 M(+26.9%) | -$5.02 M(+6.6%) | -$19.22 M(+6.1%) |
| Sep 2017 | - | -$4.71 M(-11.4%) | -$18.11 M(+7.1%) |
| Jun 2017 | - | -$5.31 M(+26.9%) | -$16.91 M(+13.9%) |
| Mar 2017 | - | -$4.19 M(+7.1%) | -$14.85 M(-1.9%) |
| Dec 2016 | -$15.15 M(+62.7%) | -$3.91 M(+11.6%) | -$15.15 M(+6.3%) |
| Sep 2016 | - | -$3.50 M(+7.7%) | -$14.24 M(+4.7%) |
| Jun 2016 | - | -$3.25 M(-27.4%) | -$13.60 M(+13.8%) |
| Mar 2016 | - | -$4.48 M(+49.1%) | -$11.95 M(+28.3%) |
| Dec 2015 | -$9.31 M(+95.0%) | -$3.01 M(+5.0%) | -$9.31 M(+17.7%) |
| Sep 2015 | - | -$2.86 M(+78.6%) | -$7.91 M(+26.3%) |
| Jun 2015 | - | -$1.60 M(-13.1%) | -$6.26 M(+12.7%) |
| Mar 2015 | - | -$1.84 M(+14.7%) | -$5.56 M(+16.3%) |
| Dec 2014 | -$4.78 M(+179.9%) | -$1.61 M(+32.7%) | -$4.78 M(+26.7%) |
| Sep 2014 | - | -$1.21 M(+35.4%) | -$3.77 M(+22.6%) |
| Jun 2014 | - | -$894.50 K(-15.9%) | -$3.08 M(+24.4%) |
| Mar 2014 | - | -$1.06 M(+77.0%) | -$2.47 M(+44.9%) |
| Dec 2013 | -$1.71 M(+119.4%) | -$601.10 K(+16.3%) | -$1.71 M(+54.4%) |
| Sep 2013 | - | -$516.70 K(+77.7%) | -$1.11 M(+87.8%) |
| Jun 2013 | - | -$290.70 K(-2.4%) | -$588.70 K(+97.6%) |
| Mar 2013 | - | -$298.00 K | -$298.00 K |
| Dec 2012 | -$778.00 K(-67.5%) | - | - |
| Dec 2011 | -$2.39 M | - | - |
FAQ
- What is Aldeyra Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics annual CFO year-on-year change?
- What is Aldeyra Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics quarterly CFO year-on-year change?
- What is Aldeyra Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Aldeyra Therapeutics?
- What is Aldeyra Therapeutics TTM CFO year-on-year change?
What is Aldeyra Therapeutics annual cash flow from operations?
The current annual CFO of ALDX is -$30.33 M
What is the all time high annual CFO for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high annual cash flow from operations is -$778.00 K
What is Aldeyra Therapeutics annual CFO year-on-year change?
Over the past year, ALDX annual cash flow from operations has changed by +$26.31 M (+46.46%)
What is Aldeyra Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ALDX is -$7.97 M
What is the all time high quarterly CFO for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high quarterly cash flow from operations is $500.40 K
What is Aldeyra Therapeutics quarterly CFO year-on-year change?
Over the past year, ALDX quarterly cash flow from operations has changed by +$50.00 K (+0.62%)
What is Aldeyra Therapeutics TTM cash flow from operations?
The current TTM CFO of ALDX is -$30.67 M
What is the all time high TTM CFO for Aldeyra Therapeutics?
Aldeyra Therapeutics all-time high TTM cash flow from operations is -$298.00 K
What is Aldeyra Therapeutics TTM CFO year-on-year change?
Over the past year, ALDX TTM cash flow from operations has changed by +$11.39 M (+27.07%)